ArticleBMJ open2018
Disease characteristics and management of hospitalised adolescents and adults with community-acquired pneumonia in China: a retrospective multicentre survey.
Article in BMJ open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02489578 (Management in Real-life of Patients Hospitalized With Community-acquired Pneumonia in China), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Management in Real-life of Patients Hospitalized With Community-acquired Pneumonia in China
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Chest physiotherapy for pneumonia in adults.The Cochrane database of systematic reviews · 2022Pooled it
- LUMINEX technology detects plasma inflammatory factor expression levels in children with severe and non-severe community acquired pneumonia.BMC pediatrics · 2026Article
- Decoding pulmonary infections through targeted next-generation sequencing: comprehensive pathogen profiling in 999 clinical cases.Frontiers in cellular and infection microbiology · 2026Article
- Application of Different Sampling Methods Combined with Metagenomic Next-Generation Sequencing to Detect Pathogens in Children with Severe Pneumonia on Mechanical Ventilation.Infection and drug resistance · 2023Article
- Overuse of medications in low- and middle-income countries: a scoping review.Bulletin of the World Health Organization · 2023Article
- Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis.International journal of environmental research and public health · 2022Article
- Associations of air pollutants with pneumonia hospital admissions in Qingdao, China: a prospective cohort study.Environmental science and pollution research international · 2022Article
- Flu-IV score: a predictive tool for assessing the risk of invasive mechanical ventilation in patients with influenza-related pneumonia.BMC pulmonary medicine · 2022Article
- Efficacy and Safety of Ceftaroline Fosamil in Hospitalized Patients with Community-Acquired Pneumonia in China: Subset Analysis of an International Phase 3 Randomized Controlled Trial.Infection and drug resistance · 2022Article
- Impact of acute kidney injury on in-hospital outcomes in Chinese patients with community acquired pneumonia.BMC pulmonary medicine · 2021Observational
- Complications of Cardiovascular Events in Patients Hospitalized with Influenza-Related Pneumonia.Infection and drug resistance · 2021Article
- Combined Neutrophil-to-Lymphocyte Ratio and CURB-65 Score as an Accurate Predictor of Mortality for Community-Acquired Pneumonia in the Elderly.International journal of general medicine · 2021Article
- A Retrospective Paired Comparison Between Untargeted Next Generation Sequencing and Conventional Microbiology Tests With Wisely Chosen Metagenomic Sequencing Positive Criteria.Frontiers in medicine · 2021Article
- Impact of reimbursement rates on the length of stay in tertiary public hospitals: a retrospective cohort study in Shenzhen, China.BMJ open · 2020Article
- Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study.BMC microbiology · 2020Article
- Disease burden and prognostic factors for clinical failure in elderly community acquired pneumonia patients.BMC infectious diseases · 2020Article
- Invasive pulmonary aspergillosis in immunocompetent patients hospitalised with influenza A-related pneumonia: a multicenter retrospective study.BMC pulmonary medicine · 2020Article
- The impact of early neuraminidase inhibitor therapy on clinical outcomes in patients hospitalised with influenza A-related pneumonia: a multicenter, retrospective study.BMC infectious diseases · 2020Article
- Impact of early neuraminidase inhibitor treatment on clinical outcomes in patients with influenza B-related pneumonia: a multicenter cohort study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- FluA-p score: a novel prediction rule for mortality in influenza A-related pneumonia patients.Respiratory research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 13 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo describe the clinical characteristics and management of patients hospitalised with community-acquired pneumonia (CAP) in China.
designThis was a multicentre, retrospective, observational study.
setting13 teaching hospitals in northern, central and southern China from 1 January 2014 to 31 December 2014
participantsInformation on hospitalised patients aged ≥14 years with radiographically confirmed pneumonia with illness onset in the community was collected using standard case report forms. PRIMARY AND SECONDARY OUTCOME MEASURES: Resource use for CAP management.
resultsOf 14 793 patients screened, 5828 with radiographically confirmed CAP were included in the final analysis. Low mortality risk patients with a CURB-65 score 0-1 and Pneumonia Severity Index risk class I-II accounted for 81.2% (4434/5594) and 56.4% (2034/3609) patients, respectively. 21.7% (1111/5130) patients had already achieved clinical stability on admission. A definite or probable pathogen was identified only in 12.7% (738/5828) patients. 40.9% (1575/3852) patients without pseudomonal infection risk factors received antimicrobial overtreatment regimens. The median duration between clinical stability to discharge was 5.0 days with 30-day mortality of 4.2%.
conclusionsThese data demonstrated the overuse of health resources in CAP management, indicating that there is potential for improvement and substantial savings to healthcare systems in China. TRIAL REGISTRATION NUMBER: NCT02489578; Results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.